Tag: avian flu treatment market report

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Avian Flu Treatment Market Through 2030?

The avian flu treatment market has experienced substantial growth in its size over recent years. It is anticipated to increase from $13.77 billion in 2025 to $15.04 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be attributed to factors such as the rising occurrence of avian influenza outbreaks, the strategic use of antiviral stockpiling, government initiatives for disease control, the expansion of infectious disease treatment within hospitals, and heightened public health awareness.

The avian flu treatment market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $20.6 billion, expanding at a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period stems from factors such as heightened investments in zoonotic disease research, the accelerating development of next-generation vaccines, an enlargement of global disease surveillance networks, a concentrated effort on swift response therapeutics, and strengthened international collaboration for pandemic readiness. Prominent trends identified for this period encompass the wider adoption of advanced antiviral therapies, an intensified focus on platforms for rapid vaccine development, the increasing application of monoclonal antibody treatments, the broadening of early diagnosis and surveillance initiatives, and an elevated emphasis on pandemic preparedness.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16352&type=smp

What Are The Main Drivers Accelerating The Growth Of The Avian Flu Treatment Market?

Increased awareness and improved diagnosis are projected to fuel the expansion of the avian flu treatment market in the coming period. Awareness refers to acknowledging a condition, whereas diagnosis involves pinpointing a particular problem stemming from that awareness. The imperative for avian flu treatment stems from the critical necessity to protect public health, avert potential pandemics, and shield poultry populations from substantial financial impacts. Effective avian flu treatment relies heavily on awareness and timely diagnosis, facilitating rapid intervention and containment measures to halt its dissemination. For example, according to the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, over 8000 individuals in the US were under active observation between February 9, 2022, and March 29, 2024, following exposure to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, the expanding awareness and improved diagnostic capabilities are propelling the growth within the avian flu treatment market.

What Are The Core Segment Classifications In The Avian Flu Treatment Market?

The avian flu treatment market covered in this report is segmented –

1) By Type: Vaccines, Antiviral Agents, Immunoglobulins

2) By Distribution Channel: Online Pharmacies, Offline Pharmacies

3) By End User: Hospital, Institutional Health Centers, Clinics

Subsegments:

1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines

2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies

3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins

Which Trends Are Contributing To Changes In The Avian Flu Treatment Market?

Leading entities within the avian flu treatment market are prioritizing the establishment of partnerships to improve effectiveness and accelerate the creation of novel therapies. These collaborations typically involve pharmaceutical firms, research organizations, and government bodies uniting to combine assets, exchange specialized knowledge, and conduct pioneering clinical studies. An illustrative example occurred in April 2024, when CureVac N.V., a biotechnology company based in Germany, collaborated with GSK plc, a pharmaceutical company from the UK, to develop an investigational influenza A (H5N1) pre-pandemic vaccine candidate. This initiative aims to counter the potential future pandemic danger presented by the H5N1 avian influenza virus. The objective of this joint venture is to assess the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which encodes an influenza A H5 antigen utilizing CureVac’s proprietary second-generation mRNA backbone. The integrated Phase 1/2 study will evaluate the vaccine candidate’s safety and efficacy among healthy adults ranging from 18 to 64 years old, as well as in older adults aged 65 to 85.

Which Industry Players Are Present In The Avian Flu Treatment Market?

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited

Access The Complete Avian Flu Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Which Region Contributes The Most To The Avian Flu Treatment Market?

North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Avian Flu Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16352&type=smp

Browse Through More Reports Similar to the Global Avian Flu Treatment Market 2026, By The Business Research Company

Influenza Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Swine Flu Vaccination Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Influenza Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Avian Flu Treatment Market Through 2030?

The avian flu treatment market has experienced substantial growth in its size over recent years. It is anticipated to increase from $13.77 billion in 2025 to $15.04 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be attributed to factors such as the rising occurrence of avian influenza outbreaks, the strategic use of antiviral stockpiling, government initiatives for disease control, the expansion of infectious disease treatment within hospitals, and heightened public health awareness.

The avian flu treatment market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $20.6 billion, expanding at a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period stems from factors such as heightened investments in zoonotic disease research, the accelerating development of next-generation vaccines, an enlargement of global disease surveillance networks, a concentrated effort on swift response therapeutics, and strengthened international collaboration for pandemic readiness. Prominent trends identified for this period encompass the wider adoption of advanced antiviral therapies, an intensified focus on platforms for rapid vaccine development, the increasing application of monoclonal antibody treatments, the broadening of early diagnosis and surveillance initiatives, and an elevated emphasis on pandemic preparedness.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16352&type=smp

What Are The Main Drivers Accelerating The Growth Of The Avian Flu Treatment Market?

Increased awareness and improved diagnosis are projected to fuel the expansion of the avian flu treatment market in the coming period. Awareness refers to acknowledging a condition, whereas diagnosis involves pinpointing a particular problem stemming from that awareness. The imperative for avian flu treatment stems from the critical necessity to protect public health, avert potential pandemics, and shield poultry populations from substantial financial impacts. Effective avian flu treatment relies heavily on awareness and timely diagnosis, facilitating rapid intervention and containment measures to halt its dissemination. For example, according to the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, over 8000 individuals in the US were under active observation between February 9, 2022, and March 29, 2024, following exposure to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, the expanding awareness and improved diagnostic capabilities are propelling the growth within the avian flu treatment market.

What Are The Core Segment Classifications In The Avian Flu Treatment Market?

The avian flu treatment market covered in this report is segmented –

1) By Type: Vaccines, Antiviral Agents, Immunoglobulins

2) By Distribution Channel: Online Pharmacies, Offline Pharmacies

3) By End User: Hospital, Institutional Health Centers, Clinics

Subsegments:

1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines

2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies

3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins

Which Trends Are Contributing To Changes In The Avian Flu Treatment Market?

Leading entities within the avian flu treatment market are prioritizing the establishment of partnerships to improve effectiveness and accelerate the creation of novel therapies. These collaborations typically involve pharmaceutical firms, research organizations, and government bodies uniting to combine assets, exchange specialized knowledge, and conduct pioneering clinical studies. An illustrative example occurred in April 2024, when CureVac N.V., a biotechnology company based in Germany, collaborated with GSK plc, a pharmaceutical company from the UK, to develop an investigational influenza A (H5N1) pre-pandemic vaccine candidate. This initiative aims to counter the potential future pandemic danger presented by the H5N1 avian influenza virus. The objective of this joint venture is to assess the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which encodes an influenza A H5 antigen utilizing CureVac’s proprietary second-generation mRNA backbone. The integrated Phase 1/2 study will evaluate the vaccine candidate’s safety and efficacy among healthy adults ranging from 18 to 64 years old, as well as in older adults aged 65 to 85.

Which Industry Players Are Present In The Avian Flu Treatment Market?

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited

Access The Complete Avian Flu Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Which Region Contributes The Most To The Avian Flu Treatment Market?

North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Avian Flu Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16352&type=smp

Browse Through More Reports Similar to the Global Avian Flu Treatment Market 2026, By The Business Research Company

Influenza Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Swine Flu Vaccination Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Influenza Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Colorectal Cancer Molecular Diagnostics Market Between 2026 And 2030?

The colorectal cancer molecular diagnostics market has experienced significant growth in recent years. Its value is expected to increase from $2.78 billion in 2025 to $3.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth in the past can be attributed to several factors, including the rising incidence rates of colorectal cancer, the expansion of diagnostic laboratory infrastructure, a growing adoption of molecular testing protocols, improved awareness regarding early screening, and the increasing application of precision medicine approaches.

The colorectal cancer molecular diagnostics market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $4.15 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the forecast period include greater investments in precision oncology, an escalating demand for minimally invasive diagnostic methods, the broadening of genomic testing initiatives, the increasing incorporation of AI into cancer diagnostics, and an intensified emphasis on monitoring treatment responses. Key trends anticipated during the same period encompass the wider acceptance of molecular biomarker testing, an increased application of PCR and sequencing technologies, a surging need for personalized oncology diagnostics, the ongoing expansion of companion diagnostic development, and a heightened concentration on the early detection of cancer.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

What Key Factors Are Shaping The Colorectal Cancer Molecular Diagnostics Market Landscape?

The expanding incidence of colorectal cancer is anticipated to drive expansion in the colorectal cancer molecular diagnostics market in the future. Colorectal cancer is a condition impacting the colon or rectum, essential components of the digestive system. This cancer arises when cells within the colon or rectum proliferate uncontrollably, leading to tumor formation. The growing occurrence of colorectal cancer consequently elevates the need for molecular diagnostics in both detecting and managing the disease. As an illustration, in March 2023, the American Cancer Society, a US-based nationwide voluntary health organization committed to eradicating cancer, estimated that approximately 153,020 individuals would be diagnosed with CRC (colorectal cancer), and about 52,550 of these individuals were projected to die from the condition. Within this group, 19,550 diagnoses and 3,750 deaths are expected to occur among individuals under the age of 50. Thus, the increasing prevalence of colorectal cancer is a significant factor propelling the growth of the colorectal cancer molecular diagnostics market.

How Is The Colorectal Cancer Molecular Diagnostics Market Categorized Across Its Segment Groups?

The colorectal cancer molecular diagnostics market covered in this report is segmented –

1) By Type: Instruments, Reagents And Kits, Services

2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)

3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Subsegments:

1) By Instruments: PCR Machines, Sequencers, Microarrays

2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs

3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services

What Market Trends Are Affecting The Colorectal Cancer Molecular Diagnostics Market?

Major companies in the colorectal cancer molecular diagnostics market are concentrating on developing innovative solutions, such as blood-based liquid biopsy screening tests. This effort aims to address the increasing demand for non-invasive, early detection tools, improve patient compliance compared to colonoscopy, and enable broader population screening as guidelines and reimbursement strategies evolve. A liquid biopsy functions as a blood test that identifies tumour-derived biomarkers from a simple blood draw; its core characteristics include minimal invasiveness, the capacity to screen asymptomatic populations, and molecular-level sensitivity. For instance, in July 2024, Guardant Health, a United States-based precision oncology company, launched Shield, a blood-based colorectal cancer screening test that received approval from the U.S. Food and Drug Administration as a primary screening option for average-risk adults aged 45 and older. Shield, a multi-marker blood assay, analyzes circulating tumour signals to identify individuals likely to have colorectal cancer; it was developed and validated within the extensive ECLIPSE clinical programme, demonstrating high sensitivity and specificity suitable for FDA primary-screening designation. The test’s composition and operation combine sequencing with proprietary bioinformatic classifiers to detect methylation and other tumour-derived signals in plasma. Its distinct advantages encompass convenience through a single blood draw, the potential to increase screening uptake, and a pathway to Medicare coverage, with applications spanning population screening and guiding positive cases to diagnostic colonoscopy, thereby offering earlier detection with fewer invasive procedures.

Which Firms Are Influencing Competition In The Colorectal Cancer Molecular Diagnostics Market?

Major companies operating in the colorectal cancer molecular diagnostics market are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Get The Full Colorectal Cancer Molecular Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Which Region Holds The Highest Market Share In The Colorectal Cancer Molecular Diagnostics Market?

North America was the largest region in the colorectal cancer molecular diagnostics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Colorectal Cancer Molecular Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Colorectal Cancer Molecular Diagnostics Market 2026, By The Business Research Company

Pancreatic Cancer Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Colorectal Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Avian Flu Treatment Market Expected To Reach Based On Its 2026 Value?

The avian flu treatment market has seen significant expansion in recent years. It is anticipated to expand from $13.77 billion in 2025 to $15.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The market’s past growth can be attributed to several factors including a rise in avian influenza outbreaks, the implementation of antiviral stockpiling strategies, government-driven disease control programs, the growth of hospital-based infectious disease treatment, and heightened public health awareness.

The avian flu treatment market is projected to experience substantial expansion in the coming years, anticipated to reach $20.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This growth during the projection period can be primarily attributed to heightened investments in zoonotic disease research, the escalating development of advanced vaccines, the broadening of global disease surveillance networks, an increased emphasis on rapid response therapeutics, and strengthened international cooperation for pandemic readiness. Key trends anticipated within this forecast timeframe encompass the wider adoption of advanced antiviral treatments, a sharpened focus on platforms for rapid vaccine creation, the increasing application of monoclonal antibody therapies, the broadening of early diagnosis and surveillance initiatives, and an intensified commitment to pandemic preparedness.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

What Major Factors Are Driving The Avian Flu Treatment Market Forward?

An increasing level of awareness and improved diagnostic capabilities are anticipated to fuel the expansion of the avian flu treatment market in the coming period. Awareness pertains to acknowledging a health state, whereas diagnosis involves pinpointing a particular problem subsequent to that acknowledgement. The necessity for avian flu treatment stems from the critical imperative to secure public health, avert potential widespread outbreaks, and shield poultry industries from substantial financial setbacks. Both awareness and timely diagnosis are vital for successful avian flu treatment, facilitating swift action and limiting its propagation. Illustratively, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 8000 people in the US were actively monitored between February 9, 2022, and March 29, 2024, following exposure to animals suspected of being HPAI A (H5N1) virus-infected. Consequently, the increased awareness and diagnosis are propelling expansion within the avian flu treatment market.

How Is The Avian Flu Treatment Market Categorized Across Its Segment Groups?

The avian flu treatment market covered in this report is segmented –

1) By Type: Vaccines, Antiviral Agents, Immunoglobulins

2) By Distribution Channel: Online Pharmacies, Offline Pharmacies

3) By End User: Hospital, Institutional Health Centers, Clinics

Subsegments:

1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines

2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies

3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins

Which Trends Are Impacting The Progress Of The Avian Flu Treatment Market?

Leading entities in the avian flu treatment market are increasingly focusing on forging partnerships to enhance efficacy and accelerate the development of new therapies. Such collaborations involve pharmaceutical firms, research organizations, and government agencies combining resources, sharing expertise, and carrying out innovative clinical trials. For example, in April 2024, CureVac N.V., a Germany-based biotechnology company, formed a partnership with GSK plc, a UK-based pharmaceutical company, to develop an investigative influenza A (H5N1) pre-pandemic vaccine candidate aimed at addressing the potential future pandemic threat presented by the H5N1 avian influenza virus. This joint venture intends to evaluate the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which utilizes CureVac’s proprietary second-generation mRNA backbone to encode an influenza A H5 antigen. The combined Phase 1/2 study will assess the vaccine candidate’s safety and effectiveness in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85.

Which Firms Are Influencing Competition In The Avian Flu Treatment Market?

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited

Get The Full Avian Flu Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Where Is The Avian Flu Treatment Market Most Concentrated Geographically?

North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Avian Flu Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Browse Through More Reports Similar to the Global Avian Flu Treatment Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Swine Flu Vaccination Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Avian Flu Treatment Market Expected To Reach Based On Its 2026 Value?

The avian flu treatment market has seen significant expansion in recent years. It is anticipated to expand from $13.77 billion in 2025 to $15.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The market’s past growth can be attributed to several factors including a rise in avian influenza outbreaks, the implementation of antiviral stockpiling strategies, government-driven disease control programs, the growth of hospital-based infectious disease treatment, and heightened public health awareness.

The avian flu treatment market is projected to experience substantial expansion in the coming years, anticipated to reach $20.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This growth during the projection period can be primarily attributed to heightened investments in zoonotic disease research, the escalating development of advanced vaccines, the broadening of global disease surveillance networks, an increased emphasis on rapid response therapeutics, and strengthened international cooperation for pandemic readiness. Key trends anticipated within this forecast timeframe encompass the wider adoption of advanced antiviral treatments, a sharpened focus on platforms for rapid vaccine creation, the increasing application of monoclonal antibody therapies, the broadening of early diagnosis and surveillance initiatives, and an intensified commitment to pandemic preparedness.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

What Major Factors Are Driving The Avian Flu Treatment Market Forward?

An increasing level of awareness and improved diagnostic capabilities are anticipated to fuel the expansion of the avian flu treatment market in the coming period. Awareness pertains to acknowledging a health state, whereas diagnosis involves pinpointing a particular problem subsequent to that acknowledgement. The necessity for avian flu treatment stems from the critical imperative to secure public health, avert potential widespread outbreaks, and shield poultry industries from substantial financial setbacks. Both awareness and timely diagnosis are vital for successful avian flu treatment, facilitating swift action and limiting its propagation. Illustratively, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 8000 people in the US were actively monitored between February 9, 2022, and March 29, 2024, following exposure to animals suspected of being HPAI A (H5N1) virus-infected. Consequently, the increased awareness and diagnosis are propelling expansion within the avian flu treatment market.

How Is The Avian Flu Treatment Market Categorized Across Its Segment Groups?

The avian flu treatment market covered in this report is segmented –

1) By Type: Vaccines, Antiviral Agents, Immunoglobulins

2) By Distribution Channel: Online Pharmacies, Offline Pharmacies

3) By End User: Hospital, Institutional Health Centers, Clinics

Subsegments:

1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines

2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies

3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins

Which Trends Are Impacting The Progress Of The Avian Flu Treatment Market?

Leading entities in the avian flu treatment market are increasingly focusing on forging partnerships to enhance efficacy and accelerate the development of new therapies. Such collaborations involve pharmaceutical firms, research organizations, and government agencies combining resources, sharing expertise, and carrying out innovative clinical trials. For example, in April 2024, CureVac N.V., a Germany-based biotechnology company, formed a partnership with GSK plc, a UK-based pharmaceutical company, to develop an investigative influenza A (H5N1) pre-pandemic vaccine candidate aimed at addressing the potential future pandemic threat presented by the H5N1 avian influenza virus. This joint venture intends to evaluate the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which utilizes CureVac’s proprietary second-generation mRNA backbone to encode an influenza A H5 antigen. The combined Phase 1/2 study will assess the vaccine candidate’s safety and effectiveness in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85.

Which Firms Are Influencing Competition In The Avian Flu Treatment Market?

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited

Get The Full Avian Flu Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Where Is The Avian Flu Treatment Market Most Concentrated Geographically?

North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Avian Flu Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Browse Through More Reports Similar to the Global Avian Flu Treatment Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Swine Flu Vaccination Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Avian Flu Treatment Market Over The 2026–2030 Period?

The avian flu treatment market has experienced robust expansion over recent years. Projections indicate it will expand from $13.77 billion in 2025 to $15.04 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. Historically, this growth can be attributed to several factors: the rising occurrence of avian influenza outbreaks, dependence on antiviral stockpiling strategies, governmental disease control programs, the broadening of hospital-based infectious disease treatment, and enhanced public health awareness.

The avian flu treatment market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $20.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.2%. This expected expansion during the forecast period is largely driven by factors such as heightened investments in zoonotic disease research, the advancing development of next-generation vaccines, the broadening of global disease surveillance networks, an increased emphasis on rapid response therapeutics, and strengthened international collaboration for pandemic preparedness. Key trends emerging in this period include a greater adoption of advanced antiviral therapies, an intensifying focus on platforms for rapid vaccine development, the growing application of monoclonal antibody treatments, the expansion of early diagnosis and surveillance initiatives, and an amplified concentration on pandemic preparedness.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16352&type=smp

What Drivers Are Expected To Influence The Avian Flu Treatment Market During The Forecast Period?

Increased understanding and identification of avian flu are anticipated to fuel expansion in the avian flu treatment market. Awareness involves perceiving a condition, whereas diagnosis pinpoints a particular problem stemming from that perception. The necessity for avian flu treatment stems from the critical imperative to protect public health, avert potential global outbreaks, and shield poultry industries from substantial financial damage. Prompt recognition and diagnosis are vital for successful avian flu management, facilitating swift action and control to stop its proliferation. For instance, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported in April 2024 that over 8000 individuals in the US were actively monitored between February 9, 2022, and March 29, 2024, following exposure to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, heightened awareness and diagnostic efforts are propelling the growth of the avian flu treatment market.

How Is The Avian Flu Treatment Market Segmented Across Key Categories?

The avian flu treatment market covered in this report is segmented –

1) By Type: Vaccines, Antiviral Agents, Immunoglobulins

2) By Distribution Channel: Online Pharmacies, Offline Pharmacies

3) By End User: Hospital, Institutional Health Centers, Clinics

Subsegments:

1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines

2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies

3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins

What Major Market Trends Are Driving Changes In The Avian Flu Treatment Market?

Companies operating in the avian flu treatment market are primarily focusing on establishing partnerships to enhance efficacy and expedite the development of new therapies. These partnerships involve collaborations between pharmaceutical enterprises, research institutions, and government bodies to consolidate resources, share expertise, and conduct innovative clinical trials. A notable example occurred in April 2024, when CureVac N.V., a Germany-based biotechnology firm, partnered with GSK plc, a UK-based pharmaceutical company, to create an investigative influenza A (H5N1) pre-pandemic vaccine candidate aimed at addressing the potential future pandemic risk posed by the H5N1 avian influenza virus. This specific collaboration intends to evaluate the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which encodes an influenza A H5 antigen using CureVac’s proprietary second-generation mRNA backbone. The upcoming combined Phase 1/2 study will assess the vaccine candidate’s safety and effectiveness in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85.

Who Are The Dominant Players Shaping The Avian Flu Treatment Market Landscape?

Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited

Read the full avian flu treatment market report here:

https://www.thebusinessresearchcompany.com/report/avian-flu-treatment-global-market-report

Which Region Is Forecast To Lead The Avian Flu Treatment Market In Terms Of Market Size?

North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Avian Flu Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16352&type=smp

Browse Through More Reports Similar to the Global Avian Flu Treatment Market 2026, By The Business Research Company

Influenza Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Swine Flu Vaccination Global Market Report

https://www.thebusinessresearchcompany.com/report/swine-flu-vaccination-global-market-report

Influenza Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model